Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Argus

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by stock analysts at Argus from a “buy” rating to a “hold” rating in a research note issued on Monday,Briefing.com Automated Import reports.

Several other equities research analysts have also weighed in on REGN. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a research note on Monday, June 2nd. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Finally, The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $822.58.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $521.00 on Monday. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $56.25 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 1.91 and a beta of 0.31. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $1,211.20. The business has a 50 day simple moving average of $554.18 and a 200-day simple moving average of $631.19.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. During the same quarter in the previous year, the firm earned $9.55 EPS. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of REGN. Capital International Investors lifted its holdings in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $802,036,000. GAMMA Investing LLC lifted its stake in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $343,764,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.